We investigated the immunogenicity of a 7-valent conjugate pneumococcal vaccine (CPV) in human immunodeficiency virus-infected Ugandan adults and measured the effect of past pneumococcal polysaccharide vaccine (PPV) receipt given as part of a controlled trial. Two doses of CPV, 4 weeks apart, were given to 54 past PPV recipients and 55 past placebo recipients (84% female; median CD4 cell count, 251 cells/mL [range, 1-936 cells/mL]). Postvaccination anticapsular immunoglobulin G (IgG) concentrations were directly correlated with CD4 cell count ( for all serotypes). P ! .01 There were significant increases in anticapsular IgG concentrations for all serotypes after the first dose ( ) and for P ! .01 all serotypes except 14 and 9V after the second dose. Past receipt of PPV did not affect vaccine response.
sociated with an inability to overcome the quantitative and functional defects in antibody responses directed against the pneumococcal capsule [5] . Moreover, there was a surprising excess of persons who developed pneumococcal-related disease. This raised concerns that exposure to PPV in the context of uncontrolled HIV may be deleterious to the immune system. We hypothesized that pneumococcal polysaccharides, which are type 2 T cell-independent antigens, might delete polysaccharide-responsive memory B cells by changing these cells into short-lived antibody-producing plasma cells. Subsequent apoptosis of these cells and a failure of replacement because of HIV-induced B cell destruction would lead to a net decrease in the ability to mount a further humoral response to pneumococcal polysaccharides.
The licensure of a 7-valent conjugate pneumococcal vaccine (CPV) and the subsequent reports of vaccine efficacy in a pediatric population with a high prevalence of HIV infection [6] led us to consider this vaccine for use in an adult population. Here, we report the findings of an immunogenicity study of CPV. The surviving participants in the original PPV study performed in Entebbe, Uganda, formed the group studied; this has provided the opportunity to investigate the impact of PPV exposure on subsequent response to rechallenge with pneumococcal polysaccharide, albeit in protein-conjugated form.
Subjects, materials, and methods. When the 23-valent polysaccharide trial ended, there was continued follow-up of participants, as part of the trial protocol [4, 7] . Between October 2001 and June 2002, past trial participants attending a routine follow-up visit were invited to participate in this open-label immunogenicity study of a 7-valent CPV (Prevnar; Wyeth-Lederle). After signing informed consent, participants received two 0.5-mL doses of vaccine, 4 weeks apart. Vaccines were given in the deltoid muscle of the nondominant arm. Serum samples were collected at baseline, at the time of the second vaccination, and 4 weeks after receipt of the second dose of vaccine. Storage and transportation of the vaccine was in accordance with manufacturer's instructions. Participants returned to the clinic 2-3 days after vaccination, to report adverse effects. A field worker visited participants who failed to attend an appointment.
Serum samples were separated within 2 h of collection and stored at Ϫ85ЊC before being shipped frozen to the Finnish National Public Health Institute. Pneumococcal serotype-specific anticapsular IgG measurements were taken for the 7 vaccine serotypes (4, 6B, 9V, 14, 18C, 19F, and 23F) by EIA with a 22F capsular polysaccharide adsorption step, as described Major adverse events, leading to hospitalization, disability, or death of an individual within 14 days, were immediately reported to the principal investigator, a local data monitor, and the vaccine suppliers (Wyeth-Lederle).
Results. One hundred eighteen participants in the previous PPV trial were approached for participation in the current trial; of these, 109 consented to participate. Ninety two (84%) were women, with a median age of 37 years (range, 24-56 years); 54 had received PPV previously and 55 had received a placebo previously. The median time from original enrollment was 62 months (range, 42-79 months). CD4 cell counts at the time of original vaccination were similar between the PPV groups (PPV vs. placebo, 504 vs. 453 cells/mL, respectively) but were significantly higher in past PPV recipients at the time of CPV vaccination (313 vs. 177, respectively; , rank sum test). P ! .01 None of the participants had received antiretroviral therapy at the time of vaccination.
Complete vaccination and sampling was achieved for 100 participants. One participant was noted to be pregnant after the first dose of vaccine and was excluded from further vaccination. The pregnancy was uncomplicated, and a healthy baby was delivered at term. Four participants died before completion of the study. One died within 2 weeks of first vaccination, but the death was judged to have been from HIV-related complications, as were the other 3 deaths. Minor adverse events were restricted to reports of self-limited sore arm (15 reports from 12 participants) and self-limited nondocumented fever (6 reports from 5 participants). There was no relationship between baseline anticapsular IgG concentration and reported adverse events. Three participants became untraceable, and 1 declined further follow-up.
Baseline concentrations of anticapsular IgG showed a direct relationship with CD4 cell counts. There was also a tendency for past PPV recipients to have a higher baseline concentration of anticapsular IgG, but this was absent when adjusted for CD4 cell count (table 1) .
There were significant increases in the geometric mean concentrations of anticapsular IgG to all vaccine serotypes (table  2) . After the second dose of vaccine, there was also a significant further increase in concentrations of anticapsular IgG to serotypes 4, 6B, 18C, 19F, and 23F. A 2-fold increase in anticapsular IgG concentration after the second dose of vaccine was achieved by a minimum of 59% of participants for serotype 14 up to 82% of participants for serotype 23F. Concentrations after the second vaccine dose were 10.35 mg/mL in 89% and 11.0 mg/mL in 75% of all samples measured. No difference in anticapsular IgG concentrations by past vaccine status were noted after the first or second vaccination (table 2) .
CD4 cell count was directly associated with postvaccination concentrations of anticapsular IgG after both the first and second dose but primarily through the association between CD4 cell count and baseline IgG concentration. In a multiple regression Discussion. HIV-infected adults are at significantly increased risk of invasive pneumococcal disease, and previous attempts to control this by vaccination with 23-valent polysaccharide pneumococcal vaccine have proven ineffective [4] . In the present study, we set out to provide the first immunogenicity data for a CPV in an African HIV-infected adult population and, in addition, to test the hypothesis that past PPV exposure had adversely biased the antipneumococcal capsular responses in this antiretroviral-untreated HIV-infected population. Significant responses to all vaccine serotypes were measured, but no effect of past PPV exposure was identified.
Significant increases in concentrations of anticapsular IgG to all serotypes were noted after the first dose of vaccine. This was expected on the basis of previous reports of CPV vaccination in HIV-infected adults from the United States [8, 9] and from the Netherlands [10] . Comparison with these previous studies is difficult, because only the most recent US study used the same 22F adsorption step in the EIA measurements. Our previous study [5] and a study by others [11] support the view that incorporating a 22F adsorption step is important for improving the specificity of the EIA for measuring anticapsular IgG in HIV-infected adults. A different dosing schedule was also used in the US study, with the second dose given after 8 rather than 4 weeks. However, after the second dose, significant further increases in concentrations of IgG to 5 of the 7 serotypes were noted in the Ugandan recipients, compared with US recipients; a greater proportion achieved a у2-fold increase; and the geometric mean concentration of anticapsular IgG was significantly higher ( ) for 4 of the 5 comparable serotypes P ! .05 after the second dose of vaccine, when the comparisons were confined to participants with CD4 cell counts of 1200 cells/mL (data not shown). An explanation for this is unclear, but it may be confounded by use of antiretrovirals. The nadir CD4 cell count before beginning antiretroviral therapy, rather than the CD4 cell count at the time of vaccination, may be an important determinant of response. It is notable that, in pediatric studies, concentrations of anticapsular IgG tend to be higher in African children than in US children, and this may reflect environmental exposure to pneumococci [12, 13] .
The post-first dose concentrations of anticapsular IgG to serotypes 19F and 23F that we reported were similar to anticapsular IgG concentrations we have reported previously after PPV, measured in the same laboratory by use of the same EIA method [5] . However, the ability to generate a further increase in anticapsular IgG concentration with a second dose of CPV suggests that the vaccine is stimulating a T cell-dependent response, albeit one that is lower in magnitude than might be seen in healthy children. The trend for fold change in concentration to increase with CD4 cell count further supports the idea of T cell involvement. CD4 cell count may be a surrogate marker of B cell counts and competence, and this would explain the baseline and post-first dose anticapsular IgG concentrations and their association with CD4 cell count. However, this would not explain the subsequent further increases in response to the second dose, suggesting further B cell stimulation-which is likely to be specific to memory B cells-rather than further responses from naive B cells. This finding raises 2 issues of practical importance. First, repeated vaccine dosing schedules should be evaluated to see if further incremental increases in anticapsular IgG concentration are achievable. Second, establishing the optimum timing of vaccination in relation to antiretroviral therapy (and the improvements in T cell function generated as a consequence of this) will need to be established as antiretroviral therapy becomes more widely available in sub-Saharan Africa.
We chose not to measure functional activity of antibodies in this population. Prior experience suggested that these measurements would add little extra information to our immunogenicity study, at the cost of much increased laboratory workload [5] . We have shown previously that the quantity of anticapsular IgG determined with EIA incorporating a 22F adsorption step correlates with measures of functional activity by a viable cell-killing assay.
A primary reason for performing the immunogenicity study in this population was to assess the effect of past PPV. In this group of subjects, response to CPV was unaffected by past PPV receipt, and our data show no direct evidence of a negative effect of PPV. Although these findings do not provide any support for a detrimental immunologic effect of PPV, neither do they exclude this possibility. The time from the original trial enrollment was long (median, 62 months), and the numbers of persons included in this study represent only 8% of the original trial cohort, most of whom have died [7] . Thus, this cohort is likely to be biased toward those who had high CD4 cell counts on original enrollment and/or who are slow progressors and, as such, may not be at high risk of detrimental effects of PPV. CD4 cell count at the time of the first dose of CPV was significantly higher in the past PPV recipients. These findings reflect the survival characteristics of this cohort and have been reported and discussed previously [7] . Because CPV responses are CD4 cell dependent, could this higher CD4 cell count have masked an adverse impact of past PPV? Incorporating CD4 cell counts into the analysis of variance models (as either a continuous or categorical variable) in all analyses led to an increase in P for the association between past PPV and postvaccination responses, compared those in with unadjusted analyses (data not shown). Thus, any masking of adverse PPV effects by higher CD4 cell counts seems unlikely. Conversely, we can be reassured that these past recipients of PPV did respond to CPV, with a sizable majority achieving a у2-fold increase in anticapsular IgG concentrations, a response greater than that achieved with reimmunization with PPV after 5 years in US HIV-infected adults [14] .
In summary, we have shown a 7-valent CPV to be immunogenic in HIV-infected adults. The achievable concentration of anticapsular IgG is strongly CD4 cell-dependent, but past PPV exposure does not seem to affect response to this vaccine. Pneumococcal disease remains an important cause of morbidity and mortality in HIV-infected Africans. Even with increased availability of antiretroviral therapy, pneumococcal disease will remain important [15] . CPVs may offer an alternative method for prophylaxis against pneumococcal disease in this population. A randomized placebo-controlled clinical efficacy trial is under way to establish their value.
